Year: 2020

MCLEAN, Va., Nov. 13, 2020 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) announces the pricing of the SB80 offering, a multifamily mortgage-backed securitization backed by small balance loans underwritten by Freddie Mac and issued by a third-party trust. The company expects to issue approximately $363 million in SB Certificates (SB80 Certificates), which are expected to settle on or about November 20, 2020. Freddie Mac Small Balance Loans generally range from $1 million to $7.5 million and are generally backed by properties with five or more units. This is the eleventh SB Certificate transaction in 2020.SB80 PricingDetails:Co-Lead Managers and Joint Bookrunners: Wells Fargo Securities, LLC and J.P. Morgan Securities LLCCo-Managers: Multi-Bank Securities, Inc., Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated...

SUGAR LAND, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) — Applied Optoelectronics, Inc. (NASDAQ: AAOI), a leading provider of fiber-optic access network products for the internet datacenter, cable broadband, telecom and fiber-to-the-home (FTTH) markets, today announced participation in the following investor conference.A live audio webcast of the presentation will be available on the investor relations section of the company’s website at investors.ao-inc.com.About Applied Optoelectronics:Applied Optoelectronics Inc. (AOI) is a leading developer and manufacturer of advanced optical products, including components, modules and equipment. AOI’s products are the building blocks for broadband fiber access networks around the world, where they are used in the internet datacenter, CATV broadband, telecom and FTTH markets. AOI supplies optical...

FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 3:15 p.m. GMT (10:15 a.m. ET).Company management will also participate in one-on-one meetings during the virtual conference which runs from November 17-19, 2020.To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.  Recordings will be available for 60 days following the...

MCLEAN, Va., Nov. 13, 2020 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) recently priced a new offering of Structured Pass-Through Certificates (K Certificates), which are backed by underlying collateral consisting of fixed-rate multifamily mortgages with predominantly 7-year terms. The company expects to issue approximately $1.1 billion in K-740 Certificates, which are expected to settle on or about November 20, 2020.K-740 PricingDetailsCo-Lead Managers and Joint Bookrunners: Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLCCo-Managers: BMO Capital Markets Corp., BofA Securities, Inc., J.P. Morgan Securities LLC and Multi-Bank Securities, Inc.Rating Agencies: Moody’s Investors Service, Inc. and Kroll Bond Rating Agency, LLCRelated LinksThe K-740 Preliminary Offering Circular Supplement: http://www.freddiemac.com/mbs/data/k740oc.pdfFreddie...

LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) —  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O’Day, Executive Director of the John Wayne Cancer Institute, Dr. Jennifer Buell, President and COO of Agenus, and Dr. Dhan Chand, Scientific Director Head of Drug Discovery at Agenus, will participate in a webcast hosted by Dr. Matt Phipps of William Blair on Monday, November 16, 2020 at 10:00 a.m. ET.Dr. Steven O’Day will review data of AGEN1181 from its ongoing Ph1 dose escalation trial and discuss the initial responses, particularly those in patients with microsatellite stable disease, and how to place these data in context with other...

PALOS VERDES ESTATES, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Malaga Financial Corporation (OTCPink:MLGF). Malaga Financial Corporation announced today that its Board of Directors had declared a special 5% stock dividend on the company’s common stock outstanding, payable on or about December 29, 2020 to shareholders of record at the close of business on December 14, 2020. The dividend will be issued in the form of additional shares of common stock. Cash will be issued in lieu of fractional shares. Additionally, a quarterly cash dividend of 25 cents was declared payable to shareholders of record at the close of business on December 14, 2020 to be paid on or about January 4, 2021. Randy C. Bowers, President and CEO, remarked, “We are pleased to declare a special year-end stock dividend in addition to our 66th consecutive quarterly...

Paris, Amsterdam, November 13, 2020Press releaseMeeting of the Supervisory Board of Unibail-Rodamco-Westfield (URW) on November 13, 2020The Supervisory Board of Unibail-Rodamco-Westfield (URW) met today in the presence of the three new directors elected at the Group’s Combined General Meeting of November 10, 2020 (Mr Léon Bressler, Ms Susana Gallardo and Mr Xavier Niel).At this meeting, the Supervisory Board took note of the resignation of the Chairman of the Board, Mr Colin Dyer, who remains a member of the Board. The Board also takes note of the resignation of Mr Jacques Stern, Vice-Chairman, and of Mr Philippe Collombel, Mrs Sophie Stabile and Mrs Jacqueline Tammenoms Bakker.The Supervisory Board appointed Mr Léon Bressler as Chairman with immediate effect. Mrs Susana Gallardo becomes member of the Governance and Nomination Committee....

Cash and cash equivalents increased by $7.7 million during the first 9 months of 2020 despite the challenging economic environment;Q3 2020 revenue from Skyline’s hotels and resorts was $25.3 million compared to $53.3 million in Q3 2019, a decline of 53% due to the impact of COVID-19;Skyline’s operating expenses from hotels and resorts also declined by 53% including the effect of subsidies received in response to the crisis;Achieved positive EBTIDA in Q3 2020 of $4.5 million, compared to negative EBITDA in Q2 2020 of $6.8 million;Q3 2020 NOI from Canadian resorts improved by 11% over Q3 2019 due to a focus on local travel;Unrestricted cash and available lines of credit as at September 30, 2020 totalled approximately $37 million;Occupancy of all of the Company’s US hotels and Canadian resorts show a steady improvement from their lows in April;...

In connection with the release of Golden Ocean’s third quarter 2020 results in the morning (CET) of Thursday, November 19, 2020, a teleconference/webcast will be held as described below:Teleconference and webcastA conference call will be held at 03:00 P.M. CET (09:00 A.M. New York Time) on Thursday, November 19, 2020. The presentation will be available for download from the Investor Relations section at www.goldenocean.bm (under “Presentations”) prior to the teleconference/webcast.In order to listen to the presentation you may do one of the following:a. WebcastClick the “Webcast” link on www.goldenocean.bmb. Conference CallPARTICIPANTS DIAL IN TELEPHONE NUMBERSParticipants will be asked for their full name & Conference ID. The Conference ID is 8433555.Please download the presentation material from www.goldenocean.bm...

LYON, Frankreich und CAMBRIDGE, Massachusetts, Nov. 13, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq und Euronext: ERYP), hat heute bekanntgegeben, dass sein CEO, Gil Beyen, auf der Jefferies Virtual London Healthcare Conference am 18. November 2020 um 12:00 Uhr EST/17:00 Uhr GMT/18:00 Uhr CET ein Update vorstellen wird.Ein Webcast der Veranstaltung wird auf der Website von ERYTECH zur Verfügung gestellt: www.erytech.com/investors/webcast/Über ERYTECH und EryaspaseERYTECH ist ein biopharmazeutisches Unternehmen, das klinische Studien zu verschiedenen Arzneimitteln durchführt und innovative Erythrozyten-basierte Therapeutika für schwere Krebserkrankungen und seltene Krankheiten entwickelt. Aufbauend auf seiner proprietären ERYCAPS®-Plattform, die eine neuartige Technologie zur Kapselung von Wirkstoffen in Erythrozyten nutzt, entwickelt...